In Brief


Clinical Roundup


Drugs & Targets
NCI Trials


NCI Trials for November 2022
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Long-awaited results from first phase III trial of a RAS inhibitor in pancreatic cancer shows that daraxonrasib doubles median OS
PanCAN’s Berkenblit: “It’s here. This is a tipping point, and we’ve tipped. And this is just the beginning.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Cancer Center at Illinois is recognized as NCI Basic Cancer Center, becoming the first new institution to earn this designation in 40 years
- Most Favored Nation drug pricing could put China on top
- NCI Director Letai wants you to know: Grant money is flowing again post-government shutdown
- Self-collection kits for HPV are among innovations adding momentum to eradication of cervical cancer
A kit for at-home unsupervised self-collection clears FDA finish line
















